mRNA-4106 / Moderna - LARVOL DELTA

Preclinical proof-of-concept of an off-the-shelf mRNA cancer antigen therapy targeting pan-tumor antigens for the treatment of multiple solid tumors (SITC 2025) - "Moderna's optimized antigen sequences enhanced tumor control and survival in a surrogate cancer model compared to wild-type sequences. Collectively, these findings establish preclinical proof-of-concept for mRNA-4106, supporting its potential as a broadly applicable, off-the-shelf mRNA cancer antigen therapy.Ethics Approval All animal experiments described in this study report were approved and conducted in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC Protocol 23-06-007)"

Pan tumor • Preclinical • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A

START Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors (PRNewswire) - "The START Center for Cancer Research...today announced the dosing of the first U.S. participant in Moderna's Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in patients with advanced or metastatic solid tumors."

Trial status • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Oncology • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Not yet recruiting | Sponsor: ModernaTX, Inc.

Checkpoint inhibition • New P1 trial • Oncology • Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Not yet recruiting | Sponsor: ModernaTX, Inc.

Checkpoint inhibition • New P1 trial • Oncology • Solid Tumor